Literature DB >> 8943172

Tall-cell variant of papillary thyroid cancer: disregarded entity?

A Rüter1, R Nishiyama, S Lennquist.   

Abstract

The tall-cell variant of papillary thyroid carcinoma (TCV) has been described as an aggressive tumor with a significantly higher incidence of recurrence and mortality than other forms of papillary carcinoma. In some series it has accounted for up to 10%, whereas in other series it has not been reported at all, indicating that there are difficulties identifying it. In a series of 162 consecutively treated patients with papillary thyroid carcinoma treated by total thyroidectomy according to a highly standardized procedure, all specimens were specifically examined by an international group of pathologists to establish the occurrence of TCV. All patients with TCV were studied with regard to local aggressiveness, the presence of metastases, iodine uptake, DNA pattern, thyroglobulin production, treatment (surgical and adjuvant), and outcome (follow-up 3-17 years, median 10 years). At primary histopathologic evaluation by the local pathologist, three patients were recorded as having TCV. At special evaluation by the expert group, eight more cases were found, giving a total of 11 patients in this series (7%). Five of them had extracapsular growth, and four were multifocal. Three had metastases at the time of admission. Seven tumors were diploid, one tetraploid, and three aneuploid. Of the three patients with primary distant metastases two died (8 and 24 months after operation), and one is still alive after 10 years. Four other patients developed recurrences, one of whom died from cardiac failure, but the others have so far been treated successfully. Two of these recurrences had no radioiodine uptake, and one had no rise in thyroglobulin concentrations; the other two had rising values that correlated with recurrence. The other four patients are alive without recurrence. It was concluded that identification of the TCV requires examination by an experienced pathologist. Moreover, it may have a higher incidence than is generally recognized. No reliable criteria for prognostic classification were identified. The results suggest that early identification and active treatment can lead to an outcome more favorable than has previously been described.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8943172     DOI: 10.1007/s002689900187

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  12 in total

Review 1.  Unusual types of thyroid cancer.

Authors:  K B Ain
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

Review 2.  Papillary carcinoma of thyroid: A 30-yr clinicopathological review of the histological variants.

Authors:  Alfred King-Yin Lam; Chung-Yau Lo; Karen Siu-Ling Lam
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

3.  Warthin tumor-like variant of papillary thyroid carcinoma: a case with dedifferentiation (anaplastic changes) and aggressive biological behavior.

Authors:  King Yin Lam; Chung Yau Lo; William I Wei
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

4.  Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma.

Authors:  Fulvio Basolo; Riccardo Giannini; Carmen Monaco; Rosa Marina Melillo; Francesca Carlomagno; Martina Pancrazi; Giuliana Salvatore; Gennaro Chiappetta; Furio Pacini; Rossella Elisei; Paolo Miccoli; Aldo Pinchera; Alfredo Fusco; Massimo Santoro
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

5.  Tall-cell variant of papillary thyroid carcinoma: a matched-pair analysis of survival.

Authors:  Luc G T Morris; Ashok R Shaha; R Michael Tuttle; Andrew G Sikora; Ian Ganly
Journal:  Thyroid       Date:  2010-02       Impact factor: 6.568

6.  Prognostic outcomes of tall cell variant papillary thyroid cancer: a meta-analysis.

Authors:  Scharukh Jalisi; Tiffiny Ainsworth; Michael Lavalley
Journal:  J Thyroid Res       Date:  2010-07-26

7.  Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma.

Authors:  A Golger; T R Fridman; S Eski; I J Witterick; J L Freeman; P G Walfish
Journal:  J Endocrinol Invest       Date:  2003-10       Impact factor: 4.256

8.  An Indian Tertiary Care Hospital Scenario of Papillary Carcinoma of Thyroid.

Authors:  Ponnuswamy Karkuzhali; Muthureddy Yogambal; Manoj Kumar
Journal:  J Clin Diagn Res       Date:  2017-06-01

9.  The tall-cell variant of papillary thyroid carcinoma: a multivariate analysis of clinical risk factors.

Authors:  Andreas Machens; Hans-Jürgen Holzhausen; Christine Lautenschläger; Henning Dralle
Journal:  Langenbecks Arch Surg       Date:  2004-05-25       Impact factor: 3.445

Review 10.  Special variants of differentiated thyroid cancer: does it alter the extent of surgery versus well-differentiated thyroid cancer?

Authors:  Tobias Carling; Idris T Ocal; Robert Udelsman
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.